Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05732831 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

A Phase 1 study of Locally Advanced Solid Tumor, sponsored by Tango Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
225
Enrollment target
20
Study locations

NCT05732831 is a Phase 1 study of Locally Advanced Solid Tumor that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 225 participants, roughly in line with the 224-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05732831, a Phase 1 study of Locally Advanced Solid Tumor, is actively recruiting participants, sponsored by Tango Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
225 participants
Enrollment target
20
Study locations

Study Summary

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Conditions Studied

Locally Advanced Solid Tumor

Interventions

  • DRUG Pembrolizumab
  • DRUG TNG462

Study Locations (20)

Other

  • CHU de Brest - Brest
  • Centre Berard Leon - Lyon
  • Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS - Saint-Herblain
  • Institute Gustav Roussy - Villejuif

Illinois

  • University Chicago Medicine - Chicago
  • Carle Cancer Center - Urbana
  • Midwestern Regional Medical Center, City of Hope Chicago - Zion

Florida

  • Florida Cancer Specialists & Research Institute - Lake Mary
  • Sylvester Comprehensive Cancer Center - Miami

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

California

  • Stanford University - Palo Alto

Colorado

  • Grand Valley Oncology - Grand Junction

Michigan

  • Henry Ford Cancer Center - Detroit

New York

  • New York University Langone Health - New York

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2023-05-26
Est. Completion 2026-09
Phase Phase 1

Sponsor

Tango Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05732831

The ClinicalTrials.gov registry entry for NCT05732831 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 224-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Tango Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05732831 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT05732831 about?

NCT05732831 is a clinical study titled "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors". This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a sel...

What is the current status of trial NCT05732831?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2023-05-26. Estimated completion is 2026-09.

What conditions does trial NCT05732831 study?

This clinical trial studies the following conditions: Locally Advanced Solid Tumor.

What interventions are being tested in trial NCT05732831?

The interventions under investigation include: Pembrolizumab (DRUG), TNG462 (DRUG).

Who is sponsoring clinical trial NCT05732831?

This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05732831 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Locally Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.